Search
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalBexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. … [A256413] SGLT2 is responsible for 60% to 90% of renal glucose re-uptake, and unlike other isoforms such as SGLT1, SGLT2 is mainly expressed in the kidney.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: D-glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1s)-, (2S,3R,4R,5S,6R)-2-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolTulobuterol
go.drugbank.com/drugs/DB12248InvestigationalTulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.
Categories: Selective Beta 2-adrenergic AgonistsBrigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigational[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. … Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).
Mixtures: ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MG, ALUNBRİG 90 MG VE 180 MG FİLM KAPLI TABLET TEDAVİYE BAŞLANGIÇ PAKETİ, 7 ADET 90 MG VE 21 ADET 180 MGCategories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, MATE 1 InhibitorsPropiverine
go.drugbank.com/drugs/DB12278ApprovedPropiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) [A32576]. … Propiverine hydrochloride is a bladder detrusor muscle relaxant drug with dual antimuscarinic and calcium-modulating properties for the treatment of OAB [L2317].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: MICTONORM SR 30MG SÜREKLI SALIMLI KAPSÜL, MICTONORM SR 45MG SÜREKLI SALIMLI KAPSÜLDasotraline
go.drugbank.com/drugs/DB12305InvestigationalDasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention
Chlorproguanil
go.drugbank.com/drugs/DB12314InvestigationalIt is a dichloro-derivative of chloroguanide.
Ifetroban
go.drugbank.com/drugs/DB12321InvestigationalIfetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.
Categories: Heterocyclic Compounds, 1-RingEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive … This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCopanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalCopanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDESamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational[A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Salts: Samidorphan L-malateCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates